alexa Serum HBV DNA and ALT Kinetics in The Trials of Antiviral Agents in Patients with Chronic Hepatitis B

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Serum HBV DNA and ALT Kinetics in The Trials of Antiviral Agents in Patients with Chronic Hepatitis B

Hepatitis B virus (HBV) infection is a widespread disease that affects about 350 million people worldwide, contributing to global public health problems and 25-40% of these will die from liver cirrhosis or primary hepatocellular carcinoma . Therapeutic tools for patients with chronic HB include the nucleoside analogue lamivudine and cytokine interferon α (IFN-α) based on several credible clinical trials

Citation: Kang J, Lee M (2011) Serum HBV DNA and ALT Kinetics in The Trials of Antiviral Agents in Patients with Chronic Hepatitis B (Appropriate sampling time for Response Assessment of Antiviral Therapy in Chronic Hepatitis B Patients). Autacoids 1:e103.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger